In addition, in the background of global H2BUb1 loss in several primary cancers including breast, lung, and colorectal cancers, H2BUb1 is selectively enriched at the coding regions of p53 target genes involved in DNA damage responses and genes involved in resistance to therapeutic drugs [39]. The gene discussed is TP53; the disease is cancer.